Skip to main content

Table 1 Demographic and clinical characteristics of the lupus patient study group

From: Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus

Demographic and clinical characteristics Number of SLE patients
Age, years 48.1 ± 14.7
Sex, female/male 113/14
Renal disease 37 (29)
Arthritis 54 (43)
Serositis 38 (30)
Haematological disorder 82 (65)
Neurological disorder 24 (19)
Immunological disorder 119 (94)
Anti-dsDNA 40 (38)
ANA 104 (82)
Anti-phospholipid syndrome 18 (14)
Low C3 27 (22)
Low C4 44 (36)
Prednisolone <7.5 mg daily 39 (31)
Prednisolone >7.5 mg daily 17 (13)
Anti-malarials 82 (65)
Azathioprine, MTX, or mycophenolate mofetil 46 (36)
SLICC/ACR Damage Index, mean ± SD (range) 0.85 ± 1.2 (0–8)
  1. Except where indicated otherwise, values are number (%) of patients
  2. Anti-dsDNA anti-double-stranded DNA, ANA anti-nuclear antigen, MTX methotrexate, SLE systemic lupus erythematosus, SLICC/ACR Systemic Lupus International Collaborating Clinics/American College of Rheumatology